

Jan Cerny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5555278/publications.pdf>

Version: 2024-02-01

75
papers

1,249
citations

361413

20
h-index

414414

32
g-index

75
all docs

75
docs citations

75
times ranked

2301
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
3	<i>TP53</i> -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. <i>Blood Advances</i> , 2022, 6, 1917-1918.	5.2	7
4	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
5	<i>Strongyloides stercoralis</i> hyperinfection syndrome in mantle cell lymphoma in post-transplant setting. <i>Annals of Hematology</i> , 2021, 100, 1089-1091.	1.8	8
6	Extramedullary Acute Myeloid Leukemia of the Renal Pelvis: Insights into a Visceral Niche. <i>Acta Haematologica</i> , 2021, 144, 297-301.	1.4	0
7	A review on how to do hematology consults during COVID-19 pandemic. <i>Blood Reviews</i> , 2021, 47, 100777.	5.7	20
8	COVID-19 related immune hemolysis and thrombocytopenia. <i>Journal of Medical Virology</i> , 2021, 93, 1164-1170.	5.0	23
9	Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside. <i>Laboratory Medicine</i> , 2021, 52, 24-35.	1.2	22
10	Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 657-662.	2.1	48
11	Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110180.	1.8	8
12	Challenges of Cellular Therapy During the COVID-19 Pandemic. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 657-672.	1.6	4
13	Role of Immunomodulation of BCG Therapy on AML Remission. <i>International Medical Case Reports Journal</i> , 2021, Volume 14, 115-119.	0.8	4
14	Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2022-2025.	1.3	1
15	Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia. <i>Blood Reviews</i> , 2021, 50, 100863.	5.7	2
16	Impact of pretransplant mutation status on survival after allogeneic stem cell transplant for acute myeloid leukemia. <i>EJHaem</i> , 2021, 2, 514-519.	1.0	0
17	Clinico-genomic profiling and clonal dynamic modeling of <i>TP53</i> -aberrant myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3348-3360.	1.3	11
18	Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant <i>Enterococcus faecium</i> Meningitis and Bacteremia. <i>Infectious Disease Reports</i> , 2021, 13, 843-854.	3.1	5

#	ARTICLE	IF	CITATIONS
19	A Splenic Infarction Related to Parainfluenza Infection in a Patient with AML: Lessons for COVID-19. <i>Acta Biomedica</i> , 2021, 92, e2021256.	0.3	0
20	A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 8841-8847.	1.9	0
21	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
22	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
23	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
24	“Because Every Drop Counts” Blood donation during the COVID-19 Pandemic. <i>Transfusion Clinique Et Biologique</i> , 2020, 27, 105-108.	0.4	23
25	Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 85, 102482.	1.4	2
26	Convalescent plasma therapy: A passive therapy for an aggressive COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2251-2253.	5.0	17
27	COVID-19 pandemic and impact on hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2193-2195.	2.4	36
28	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2191-2199.	1.3	4
29	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	2.5	58
30	Managing patients with hematological malignancies during COVID-19 pandemic. <i>Expert Review of Hematology</i> , 2020, 13, 787-793.	2.2	20
31	Challenges for management of immune thrombocytopenia during COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2020, 92, 2277-2282.	5.0	43
32	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
33	Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 83, 102439.	1.4	22
34	Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. <i>British Journal of Haematology</i> , 2020, 190, e86-e89.	2.5	31
35	Chronic neutrophilic leukemia, a rare case of leukocytosis. <i>Leukemia Research</i> , 2020, 94, 106384.	0.8	2
36	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22

#	ARTICLE	IF	CITATIONS
37	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
38	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
39	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
40	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
41	Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based (5 + 1) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 209-215.	4.1	8
42	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
43	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
44	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
45	Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. <i>Journal of Clinical Apheresis</i> , 2018, 33, 431-435.	1.3	2
46	Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns. <i>Drugs and Aging</i> , 2018, 35, 1055-1064.	2.7	4
47	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
48	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
49	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. <i>Blood</i> , 2018, 132, 3456-3456.	1.4	0
50	High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1430-1430.	1.4	0
51	Hematopoietic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 1396-1396.	1.4	0
52	Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination. <i>Annals of Hematology</i> , 2017, 96, 1563-1568.	1.8	5
53	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
54	Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia—A Velocity Vector Imaging Analysis. <i>Echocardiography</i> , 2016, 33, 1166-1177.	0.9	20

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
56	A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study. <i>Blood</i> , 2016, 128, 4053-4053.	1.4	1
57	Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity. <i>Journal of Clinical Apheresis</i> , 2015, 30, 367-370.	1.3	8
58	A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. <i>Science Translational Medicine</i> , 2014, 6, 252ra121.	12.4	105
59	Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation. <i>Leukemia Research Reports</i> , 2014, 3, 51-53.	0.4	3
60	PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1790-1790.	1.4	21
61	Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2268-2268.	1.4	4
62	Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG). <i>Blood</i> , 2014, 124, 1152-1152.	1.4	0
63	Novel FGFR3 rearrangement t(4;22)(p16;q11.2) in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1433-1435.	1.8	5
64	Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , 2013, 160, 262-266.	2.5	49
65	High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT. <i>Blood</i> , 2013, 122, 4554-4554.	1.4	1
66	Why Does My Patient Have Leukocytosis?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 303-319.	2.2	24
67	Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A Single Institution Experience. <i>Blood</i> , 2011, 118, 4505-4505.	1.4	0
68	Mutations in Bone Marrow-Derived Stromal Stem Cells Unmask Latent Malignancy. <i>Stem Cells and Development</i> , 2010, 19, 1153-1166.	2.1	34
69	High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 3290-3290.	1.4	1
70	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. <i>Hematology</i> , 2009, 14, 187-197.	1.5	1
71	Coronary Vasospasm with Myocardial Stunning in a Patient with Colon Cancer Receiving Adjuvant Chemotherapy with FOLFOX Regimen. <i>Clinical Colorectal Cancer</i> , 2009, 8, 55-58.	2.3	28
72	Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. <i>European Journal of Haematology</i> , 2008, 81, 65-69.	2.2	37

#	ARTICLE	IF	CITATIONS
73	Mesenchymal Stem Cells (MSC) Promote Aggressive Behavior of Human Breast Cancer Cells (MCF-7) in Vitro- the Role Cytokines (TNF-alpha) and Chemokines. Blood, 2008, 112, 4750-4750.	1.4	0
74	Chromatin remodeling and stem cell theory of relativity. Journal of Cellular Physiology, 2004, 201, 1-16.	4.1	60
75	Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. British Journal of Haematology, 2000, 108, 629-640.	2.5	20